Skip to main content
SpringerLink
Log in

Production of highly purified no-carrier-added 177Lu for radioimmunotherapy

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

No-carrier-added 177Lu produced via the 176Yb(n, γ)177Yb → 177Lu process was separated from the macroscopic amounts of the Yb target using reversed-phase ion-pair liquid chromatography. To produce a highly purified 177Lu solution capable of labeling antibodies, the metallic impurities were removed using cation, chelating ion, and anion exchange columns. After the elimination of metallic impurities, the concentrations of Ca, Fe, and Zn were reduced from 87, 340, and 77 ppb to 13, 18, and 9 ppb, respectively. Consequently, the labeling yield of the 177Lu-labeled antibody increased from <5 to 88 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Coldenberg DM, Oyen WJG, Boerman OC (2004) J Nucl Med 45:1224–1232

    CAS  Google Scholar 

  2. Brouwers AH, van Eerd JEM, Frielink C, Oosterwijk E, Oyen WJG, Corstens FHM, Boerman OC (2004) J Nucl Med 45:327–337

    CAS  Google Scholar 

  3. Kwekkeboom DJ, Temissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) J Clin Oncol 23:2754–2762

    Article  CAS  Google Scholar 

  4. Kam BLR, Teunissen JJM, Krennig EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ (2012) Eur J Nucl Med 39:S103–S112

    Article  Google Scholar 

  5. Grünberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Bläuenstein P, Ametamey S, Maecke HR, Schubiger PA (2005) Clin Cancer Res 115:112–5120

    Google Scholar 

  6. Persson M, Gedda L, Lundqvist H, Tolmachev V, Nordgren H, Malmström P, Carlsson J (2007) Cancer Res 67:326–331

    Article  CAS  Google Scholar 

  7. Forrer F, Unsijarvi H, Storch D, Maecke HR, Muell-Brand J (2005) J Nucl Med 46:1310–1316

    CAS  Google Scholar 

  8. Knogler K, Grünberg J, Novak-Hofer I, Zimmermann K, Schubiger PA (2006) Nucl Med Biol 33:883–889

    Article  CAS  Google Scholar 

  9. Rasaneh S, Rajabi H, Babaei MH, Daha FJ (2010) Nucl Med Biol 37:949–955

    Article  CAS  Google Scholar 

  10. Salouti M, Babaei MH, Rajabi H, Javad Rasaee M (2011) Nucl Med Biol 38:849–855

    Article  CAS  Google Scholar 

  11. Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ (2003) Nucl Med Biol 30:101–109

    Article  CAS  Google Scholar 

  12. Beckford Vera DR, Eigner S, Eigner Henke K, Lebeda O, Melichar F, Beran M (2012) Nucl Med Biol 39:3–13

    Article  CAS  Google Scholar 

  13. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) Eur J Nucl Med 28:1319–1325

    Article  CAS  Google Scholar 

  14. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BLR, van Essen M, Krenning EP, Kwekkeboom DJ (2008) Eur J Nucl Med Mol Imaging 35:749–755

    Article  CAS  Google Scholar 

  15. Knapp FF Jr, Mirzadeh S, Beets AL, Du M (2005) J Radioanal Nucl Chem 263:503–509

    Article  CAS  Google Scholar 

  16. Lahiri S, Nayak D, Nandy M, Das NR (1998) Appl Radiat Isot 49:911–913

    Article  CAS  Google Scholar 

  17. Lebedev NA, Novgorodoov AF, Misiak R, Brockmann J, Rösch F (2000) Appl Radiat Isot 53:421–425

    Article  CAS  Google Scholar 

  18. Chakravaty R, Das T, Dash A, Venkatesh M (2010) Nucl Med Biol 37:811–820

    Article  Google Scholar 

  19. Bilewicz A, Żuchowska K, Bartoś B (2009) J Radioanal Nucl Chem 280:167–169

    Article  CAS  Google Scholar 

  20. Balasubramanian PS (1994) J Radioanal Nucl Chem 185:305–310

    Article  CAS  Google Scholar 

  21. Mirzadeh S, Du M, Beets AL, Knapp Jr FF (2004) United States Patent No. 6,716,353, April 6, 2004

  22. So LV, Morcos N (2008) J Radioanal Nucl Chem 277:651–661

    Article  Google Scholar 

  23. So LV, Morcos N, Zaw M, Pellegrini P, Greguric I (2008) J Radioanal Nucl Chem 277:663–673

    Article  Google Scholar 

  24. So LV, Morcos N, Zaw M, Pellegrini P, Greguric I, Nevissi A (2008) J Radioanal Nucl Chem 277:675–683

    Article  Google Scholar 

  25. Horwitz EP, McAlister DR, Bond AH, Barrans RE, Williamson JM (2005) Appl Radiat Isot 63:23–36

    Article  CAS  Google Scholar 

  26. Hashimoto K, Matsuoka H, Uchida S (2003) J Radioanal Nucl Chem 255:575–579

    Article  CAS  Google Scholar 

  27. Paudyal P, Paudyal B, Iida Y, Oriuchi N, Hanaoka H, Tominaga H, Ishikita T, Yoshioka H, Higuchi T, Endo K (2009) Oncol Rep 22:115–119

    Article  CAS  Google Scholar 

  28. Mukai T, Namba S, Arano Y, Ono M, Fujioka Y, Uehara T, Ogawa K, Konishi J, Saji H (2002) J Pharm Pharmacol 54:1073–1081

    Article  CAS  Google Scholar 

  29. Dadachova E, Mirzadeh S, Smith SV, (Russ) Knapp Jr FF, Hetherington EL (1997) Appl Radiat Isot 48:477–481

  30. NIST Standard Reference Database 46 http://www.nist.gov/srd/nist46.cfm. Accessed 24 Feb 2014

  31. Saito N (1984) Pure Appl Chem 56:523–539

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. N. Seko of the Quantum Beam Science Center of the Japan Atomic Energy Agency for his helpful assistance with the ICP-MS analyses. This study is the result of “Development of RI-DDS for advanced cancer diagnosis and therapy” carried out under the Strategic Promotion Program for Basic Nuclear Research by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Author notes

  1. Yasuhiko Iida

    Present address: Suzuka University of Medical Science, Suzuka, Mie, 510-0293, Japan

  2. Keigo Endo

    Present address: Kyoto College of Medical Science, Nantan, Kyoto, 622-0041, Japan

Authors and Affiliations

  1. Quantum Beam Science Center, Japan Atomic Energy Agency, Takasaki, Gunma, 370-1292, Japan

    Satoshi Watanabe, Shigeki Watanabe & Noriko S. Ishioka

  2. Quantum Beam Science Center, Japan Atomic Energy Agency, Tokai-mura, Ibaraki, 319-1195, Japan

    Kazuyuki Hashimoto

  3. Department of Bioimaging Information Analysis, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan

    Yasuhiko Iida & Hirofumi Hanaoka

  4. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan

    Keigo Endo

Authors
  1. Satoshi Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuyuki Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiko Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirofumi Hanaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keigo Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noriko S. Ishioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Watanabe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watanabe, S., Hashimoto, K., Watanabe, S. et al. Production of highly purified no-carrier-added 177Lu for radioimmunotherapy. J Radioanal Nucl Chem 303, 935–940 (2015). https://doi.org/10.1007/s10967-014-3534-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-014-3534-y

Keywords

Search

Navigation